Dwarikesh Sugar Industries Ltd. — Call Transcript 2022

Apr 29, 2022

==> picture [95 x 78] intentionally omitted <==

DWARIKESH SUGAR INDUSTRIES LIMITED

Corp. off.; 511, Maker Chambers V, 221, Nariman Point, Mumbai – 400021. Tel.: 2283 2486, 2204 2945, Fax : 2204 7288 E Mail : dsilbom@dwarikesh.com Website : www.dwarikesh.com, CIN : L15421UP1993PLC018642

REF: DSIL/2022-23/066 April 29, 2022

Corporate Relationship Department National Stock Exchange of India Limited BSE Limited “Exchange Plaza” Phiroze Jeejeebhoy Towers Bandra – Kurla Complex, Dalal Street, Fort, Mumbai - 400 001 Bandra [E], Mumbai - 400 051 Fax: 22723 2082 /3132

Scrip Code - 532610 Scrip Code – DWARKESH

Sub: Conference call with respect to financial results for quarter and year ended March 31, 2022 and Outlook

Dear Sir,

Pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that a conference call on Wednesday, May 04, 2022 at 3.00 p.m. (IST) w.r.t. financial results for the quarter and year ended March 31, 2022 and outlook of the company is organized by B & K SECURITIES (Batlivala & Karani Securities India Pvt. Ltd.) as per details in the annexed invite (copy of invite is attached).

Kindly take the same on record.

Thanking you,

Yours faithfully,

BALKISHAN Digitally signed by BALKISHAN JAWARILAL JAWARILAL MAHESHWARI MAHESHWARI Date: 2022.04.29 10:59:58 +05'30'

B. J. Maheshwari

Managing Director & CS cum CCO DIN: 00002075

Encl: as above

Regd. Office & factory : Dwarikesh Nagar – 246 762, Dist. Bijnor, (U.P.) * Tel.: 01343 – 267057-64 *Fax : 01343 - 267065

==> picture [472 x 96] intentionally omitted <==

CONCALL INVITE

B&K Securities shall hold

a Conference Call of Dwarikesh Sugar Industries Ltd.

CIN : L15421UP1993PLC018642

to discuss the Q4FY22 Financial performance

on Wednesday, 4[th] May 2022 at 3:00 pm IST

The Management Team will be represented by: – Mr. Vijay S. Banka Managing Director You are cordially invited to join the conference call

Diamond Pass Link

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=023538 3&linkSecurityString=100ad6951

Dial-in Numbers

Universal Dial-in

+91 22 6280 1222/+91 22 7115 8123

International Toll Free

UK 08081011573

USA 18667462133 HongKong +852 30186877 Singapore +65 31575746

For further information, please contact

Mr. Anupam Goswami

Batlivala & Karani Securities India Pvt. Ltd.

+91 90511 63951

anupam.goswami@bksec.com

Regards

B&K Research research.equities@bksec.com +91-22-4031 7000

Disclaimer

This report was prepared, approved, published and distributed by Batlivala & Karani Securities India Private Limited (“B&K”) located outside of the United States (a “non-US Group Company”), which accepts responsibility for its contents. It is distributed in the U.S. by Enclave Capital, a U.S. registered broker dealer, on behalf of B&K, only to major U.S. institutional investors (as defined in Rule 15a6 under the U.S. Securities Exchange Act of 1934 (the “Exchange Act”) pursuant to the exemption in Rule 15a-6. Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. (“FINRA”) or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. Outside the United States, this report is distributed by B&K or an authorized affiliate of B&K.

The report has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. B&K has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, B&K accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. B&K provides the information for the purpose of the intended recipient’s analysis and review and recipients are advised to verify the factual accuracy, assumptions, calculations and completeness of the information.

This report was produced by B&K solely for information purposes and for the use of the recipient. It is not to be reproduced, redistributed under any circumstances and is not to be copied or made available to any person other than the recipient. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions. This document does not constitute an offer of, or an invitation by or on behalf of B&K or its affiliates or any other company to any person, to buy or sell any security.

The views of any Analyst reflected in this report are given in compliance with the Research Analyst Regulations, 2014. All analysts covering the securities/ companies mentioned in this report have complied with the appropriate set of rules, regulations & procedures in their detailed coverage report(s) of the respective securities/companies. It is important to note that any dispute with respect to this Research Report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

1. B&K or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report. 2. B&K or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.

2. B&K or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the p ast 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities w ithin the next three months.

3. However, one or more person of B&K or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their

clients.

1. B&K or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or t he research or analysis on which they are based before the material is published to recipients and from time to time provide inv estment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securiti es business from, any entity referred to in this report.

2. As of the publication of this report, Enclave Capital does not make a market in the subject securities.

Important US Regulatory Disclosures on Subject Companies

Enclave Capital is the distributor of this document in the United States of America. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital and any tra nsaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital (19 West 44t h Street, suite 1700, New York, NY 10036). Tel No: (646) 454 8600).

Unsubscribe from this distribution